Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessSenior Chinese health official admits Chinese vaccines ‘don't have very high protection...

Senior Chinese health official admits Chinese vaccines ‘don’t have very high protection rates’

Add to Favorite
Added to Favorite

 

In an unprecedented move, the Director of the China Centers for Disease Control Gao Fu admitted that Chinese vaccines “don’t have very high protection rates.” The health official was speaking at a conference on Saturday in Chengdu, a city in southwestern China.

 

Gao also that the country was formally considering whether they should use different vaccines from different technical lines for the process of immunization.

 

On Sunday, at a news conference, officials did not respond when asked about Gao’s comment or whether there has been an official change in plans. A CDC official mentioned that developers were working on mRNA vaccines.

 

The official, Wang Huaqing said that that the mRNA vaccines developed in China had “entered the clinical trial stage” but no timeline for use was mentioned by him.

 

Earlier, China had distributed several millions of Sinovac vaccines to Brazil, Mexico, Turkey, Indonesia and more. Beijing was looking to undermine the Pfizer-BioNTech vaccine while promoting the effectiveness of its indigenous Sinovac vaccine

 

However, Sinovac has efficiency as low as 50.4 percent in preventing symptomatic infections according to researchers in Brazil. The threshold at which a vaccine is considered useful by health experts is 50 percent. The Pfizer-BioNTech vaccine has an efficacy rate of 97 percent.

 

A Sinovac spokesman Liu Peicheng said that varying levels of effectiveness have been seen but he attributed this to different factors such as age of people in a study, the virus strain and other reasons.

 

Earlier Gao, Chinese media and health and science blogs in China had questioned both the safety and the efficacy of the Pfizer vaccine. Now, Beijing is conducting research and clinical trials, using the same type of vaccine – mRNA that Pfizer and Moderna used to develop their efficient vaccines.

 

Experts say mixing vaccines might increase effectiveness. British researchers are experimenting on a combination of the traditional AstraZeneca vaccine and the new mRNA Pfizer-BioNtech vaccine to check whether this vaccine is more effective.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Alight, Inc. (NYSE: ALIT) Q3 Earnings Overview

Alight reported a Q3 earnings per share (EPS) of...

Triumph Group’s Financial Performance and Market Outlook

Triumph Group (NYSE:TGI) surpasses analysts' expectations with its second-quarter...

Applied Materials, Inc. (NASDAQ:AMAT) Overview: A Key Player in the Semiconductor Industry

The consensus price target for NASDAQ:AMAT is $245, indicating...